Skip to Content
  • The Drug Project Landscape

    Here’s a new paper in Nature Reviews Drug Discovery that’s going to the trouble of matching specific disease indications with specific mechanisms in… Read More
  • PARP Inhibitors Come Through

    PARP (poly ADP-ribose polymerase) inhibitors have had a rough time of it in the clinic. Sanofi had one (iniparib) fail, but it later turned out, embarrassingly… Read More
  • Translation Needed

    The “Opinionator” blog at the New York Times is trying here, but there’s something not quite right. David Bornstein, in fact, gets off on the… Read More
  • Those Me-Too Drugs

    So, me-too drugs, knock-offs, copycats: what say you? If you’re a critic of the industry, you generally say quite a bit, and it’s about lack of inno… Read More
  • Biosimilars: Not So Dang Easy

    This post drew a lot of comments here about how the big companies are going after follow-on biologic drugs. As a late-2008 article put it: Merck already has one… Read More
Page 1 of 41234